Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
What strategies do you implement to control the nausea from Enhertu?
Related Questions
In patients with both ESR1 and PIK3CA mutations who have progressed on AI+CDK4/6 inhibitor, how are you deciding the treatment/sequence of next-line therapies?
In a patient with metastatic HR+/HER2- breast cancer who progressed on adjuvant hormonal therapy, do you start fulvestrant + CDK4/6i or do you wait for NGS testing to determine eligibility for targeted agents such as elacestrant or PIK3CA inhibitors?
What would be your approach to first line therapy for patient with metastatic HER2 positive breast cancer with CHF (LVEF <50%)?
What are your top takeaways from SABCS 2023?
How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?
Do you recommend the use of elacestrant after prior fulvestrant in metastatic hormone positive breast cancer?
In metastatic hormone receptor positive breast cancer, would you consider combination exemestane and CDK4/6 inhibitor if letrozole and anastrazole are not tolerated?
Would you consider using trastuzumab deruxtecan in a patient with progressive HR+ breast cancer that is HER2 2+ with prior history of cell cycle inhibitor related pneumonitis?
What is the current paradigm for breast cancer diagnosed with isolated metastases prior to initial treatment?
Is there a role for systemic therapy in recurrent oligometastatic triple negative breast cancer with brain only disease?
